Autolus Therapeutics plc - Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share (AUTL)

Historical Holders from Q2 2018 to Q3 2025

Symbol
AUTL on Nasdaq
Type / Class
Equity / Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share
Shares outstanding
266M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
143M
Holdings value
$234M
% of all portfolios
0.001%
Grand Portfolio weight change
0%
Number of holders
94
Number of buys
46
Number of sells
-35
Average Value change %
+0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Autolus Therapeutics plc - Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share (AUTL)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Syncona Portfolio Ltd 10.8% $37.8M 28.8M Syncona Portfolio Limited 31 Mar 2025
MAK Capital Fund LP 10.1% +71.7% $34.4M $14.7M 26.9M +74.5% MAK Capital Fund LP 01 Dec 2025
ARMISTICE CAPITAL, LLC 5.86% $25.4M 15.6M Armistice Capital, LLC 30 Sep 2025
FMR LLC 3.8% $13.3M 10.2M FMR LLC 31 Mar 2025
Deep Track Capital, LP 0.97% $4.19M 2.57M Deep Track Capital, LP 30 Sep 2025

Institutional Holders of Autolus Therapeutics plc - Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share (AUTL)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 143M $234M -$67.6M $1.63 94
2025 Q2 166M $378M +$9.84M $2.28 93
2025 Q1 168M $261M -$3.53M $1.55 93
2024 Q4 168M $395M -$37.1M $2.35 107
2024 Q3 179M $648M +$2.54M $3.63 97
2024 Q2 178M $620M -$54.5M $3.48 106
2024 Q1 176M $1.12B +$380M $6.38 114
2023 Q4 116M $746M +$30.3M $6.44 97
2023 Q3 111M $258M +$2.93M $2.33 67
2023 Q2 109M $260M +$12.4M $2.38 67
2023 Q1 106M $195M -$3.03M $1.84 64
2022 Q4 107M $204M +$110M $1.90 69
2022 Q3 49.4M $106M -$3.35M $2.14 62
2022 Q2 50.8M $144M -$7.12M $2.83 57
2022 Q1 45.7M $191M -$17.8M $4.17 60
2021 Q4 52.5M $272M +$102M $5.19 69
2021 Q3 25.1M $164M -$2.14M $6.55 55
2021 Q2 25.4M $170M +$23.3M $6.64 64
2021 Q1 22.4M $128M +$53.7M $5.73 58
2020 Q4 12.6M $113M +$962K $8.94 46
2020 Q3 12.4M $143M -$24.8M $11.64 44
2020 Q2 14.3M $230M -$16.4M $16.03 48
2020 Q1 16M $96.4M +$6.94M $5.99 50
2019 Q4 13.4M $177M +$749K $13.20 54
2019 Q3 13.4M $167M -$101M $12.42 42
2019 Q2 21.4M $344M +$52.5M $16.10 45
2019 Q1 18.1M $569M +$34M $31.47 32
2018 Q4 17M $558M -$24.1M $32.84 36
2018 Q3 17.9M $546M +$275M $30.66 39
2018 Q2 9.01M $241M +$237M $26.79 49